Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01739634

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Sponsor: Salient Pharmaceuticals Incorporated

Conditions Diarrhea Medullary Thyroid Cancer

Interventions CASAD

Updated 5 times since 2017 Last updated: Nov 29, 2012 Started: Nov 30, 2012 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diarrhea and Medullary Thyroid Cancer and is currently ongoing. Salient Pharmaceuticals Incorporated leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Feb 2017 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Salient Pharmaceuticals Incorporated

Data source: Salient Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States